GlucoTrack (GCTK) investor relations material

Company overview and business model

• Operates as a holding company with two subsidiaries: one focused on clinical-stage biopharmaceuticals (LT-100 for OA and MS) and another on implantable continuous blood glucose monitoring for diabetes.

• LT-100 is a bee venom-based therapy for inflammation and pain in knee OA and MS, with clinical data from South Korea and ongoing U.S. trials.

• Glucotrack Technologies develops a long-term implantable glucose monitor, targeting Type 1 and insulin-using Type 2 diabetics, with demonstrated 3-year sensor longevity.

• The company leverages academic collaborations for business development and talent through its ai² Futures Lab platform.

Financial performance and metrics

• As of March 31, 2026, had an accumulated deficit of approximately $156.2 million and cash/cash equivalents of $3.9 million.

• Net tangible book value as of June 30, 2026, was $(1,741,000), or $(4.17) per share; adjusted net tangible book value post-offering would be $22.7 million, or $2.14 per share.

• The company has a history of losses and may not achieve profitability without additional capital.

Use of proceeds and capital allocation

• No proceeds from selling stockholders; may receive up to $50 million from ELOC Purchase Agreement, $4 million from PIPE Common Warrants, and $33.3 million from September Warrants and PA Warrants.

• 25% of ELOC proceeds must repay Bridge Investors; 50% allocated to Glucotrack Technologies; remainder for working capital and general corporate purposes.